Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that its Trials in Progress abstract has been selected for ...

On January 30, 2025, Akero closed an underwritten public offering of 6.427 million common shares at $48.00 per share and ...